  Quantitative decision-making (QDM) principles address the issues related to
the mapping of results to decisions, the synthesis of information and the
quantification of uncertainty. Since the clinical drug development involves a
succession of decisions to be made, QDM methods can be applied at various
levels. At the study level, it can be used to properly design a study, and
improve the decisions that are made either during the trial or at its end.
Establishing decision criteria ahead of the study is essential here to address
the need for speedy decisions, potentially in real time. At the project level,
QDM can be used to inform decisions to continue, adapt or stop a drug
development programme based on results from previous studies. At the portfolio
level, QDM can be used to choose, prioritise and optimise the development
portfolio, e.g. using the probability to reach market access or target sales
within a predefined timeline. The increasing interest in QDM and its
statistical nature led in 2017 to the development a cross-industry and academia
Special Interest Group on QDM within the Society and the European Federation of
Statisticians in the Pharmaceutical Industry (PSI and EFSPI). The activities of
the group included discussing QDM examples, some published in the literature
and some real anonymised ones covering several settings. While the
methodologies, and to some extent the terminology, employed also varied
depending on the context, discussions within the group distilled common
principles to be considered when implementing QDM, particularly around the
construction of QDM frameworks, assessment of operating characteristics and
communication with the clinical team. The present manuscript presents those
points to consider, hoping they can be helpful to statisticians interested in
implementing QDM.
